← Back to Search

Mushroom-based Product

Mushroom-based Product for COVID-19 (MACH19 Trial)

Phase 1 & 2

Waitlist Available

Led By Andrew Shubov, MD

Research Sponsored by Gordon Saxe

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

MACH19 Trial Summary

This trial will compare two types of mushrooms to see if they help treat mild-to-moderate symptoms of COVID-19 in people who are self-quarantining at home. A total of 66 people will be in the study.

Eligible Conditions

COVID-19
Coronavirus

MACH19 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adverse Events

Alanine transaminase

Aspartate transaminase

+3 more

Secondary outcome measures

C-Reactive Protein

D-Dimer

Mental disorders

+10 more

MACH19 Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: MushroomsExperimental Treatment1 Intervention

Fomitopsis officinalis and Trametes versicolor

Group II: PlaceboPlacebo Group1 Intervention

Organic brown rice

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Gordon SaxeLead Sponsor

University of California, Los AngelesOTHER

1,528 Previous Clinical Trials

10,276,797 Total Patients Enrolled

21 Trials studying COVID-19

873,550 Patients Enrolled for COVID-19

University of California, IrvineOTHER

542 Previous Clinical Trials

1,921,947 Total Patients Enrolled

6 Trials studying COVID-19

2,210 Patients Enrolled for COVID-19

Media Library

FoTv (Mushroom-based Product) Clinical Trial Eligibility Overview. Trial Name: NCT04667247 — Phase 1 & 2

COVID-19 Clinical Trial 2023: FoTv Highlights & Side Effects. Trial Name: NCT04667247 — Phase 1 & 2

FoTv (Mushroom-based Product) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04667247 — Phase 1 & 2

COVID-19 Research Study Groups: Mushrooms, Placebo

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any patients currently needed to enroll in this research project?

"The clinical trial in question, which was first posted on December 3rd 2020, is not currently looking for any participants. This is according to the information available on clinicaltrials.gov. The last time this study was edited was October 31st 2022. There are 1129 other trials that are presently recruiting patients."

Answered by AI

What are the goals that participants of this clinical trial hope to achieve?

"The purpose of this study is to observe the effects of Creatinine over a 2-month period. Additionally, we will be exploring how treatment affects Ventilatory requirement, D-Dimer, and Lymphocyte count as possible indicators of COVID-19 severity."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Mushroom-based Product for COVID-19

Gordon Saxe 2020. "Mushroom-based Product for COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04667247.